Fireside Chat: Beyond PD-1xVEGF- What’s Next for Bispecifics, Emerging Modalities & Non-Oncology Applications?
- Which novel targets and multispecific formats, including bispecific ADCs, could reshape the bispecific and TCE landscape over the next decade, in oncology and beyond?
- As companies move past conventional antibody bispecifics, which strategies or modalities show the most promise for sustained clinical impact, particularly in chronic dosing and non-oncology settings?
- What does multi-targeting enable biologically, and when does added complexity translate into real functional or clinical benefit in long-term and non-oncology treatment paradigms?
- Which early clinical or translational lessons are shaping target selection, modality choice, trial design, and dosing strategies for next-generation multispecifics across oncology and non-oncology indications?